**Suppl 1.** Review of Reported Listeria Infections Under Biological Drugs

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Px** | **Authors** | **Origin (year)** | **Age group** | **Product and no. of doses** | **Indication** | **Concomitant immunosuppressant/immunomodulator drugs** | **Type of infection** | **Outcome** |
| 1 | Abreu, C., Magro, F., Vilas-Boas, F., Lopes, S., Macedo, G. and Sarmento, A. [2] | Portugal  (2013) | 51F | Infliximab (x2 infusions) | UC | Steroids | *L. monocytogenes* meningitis | Managed with ampicillin & meropenem; recovered; nil adverse clinical or neurological sequelae; asymptomatic on 5-ASA maintenance therapy; infliximab was not reintroduced |
| 2 | 69M | Infliximab (x2 infusions) | UC | Steroids, azathioprine | *L. monocytogenes* meningitis | Received 3-week course of ampicillin & gentamicin for first week; recovered with no clinical or neurological sequelae; infliximab reintroduced 4 months after completing meningitis treatment |
| 3 | Parihar V, Maguire S, Shahin A, Ahmed Z, O’Sullivan M, Kennedy M et al. [8] | Ireland  (2015) | 37M | Infliximab (x1 infusion)  10 days after receiving first infusion of infliximab | UC | Steroids | *L. monocytogenes* meningitis | Steroids suspended; prescribed 10-day course of IV amoxicillin and gentamicin. Recovered with no neurological sequelae. Subtotal colectomy was eventually performed with no further anti-TNFa therapy. |
| 4 | Inoue T, Itani T, Inomata N, Hara K, Takimoto I, Iseki S et al. [9] | Japan (2017) | 80M | Not initiated on infliximab | UC | A1: PO prednisolone 20 mg/day added to 5-ASA maintenance  A2: PO prednisolone 30 mg/day and azathioprine | *L. monocytogenes* septicemia caused by enteritis complicating UC and meningitis; *Candida* septicemia & pulmonary aspergilloma | Treated with IV ampicillin (Listeria infection); gradually recovered with antifungal therapy (Candida infection); tazobactam/piperacillin added for empiric cover; required prolonged hospital stay; UC well-controlled - eventually treated with immunomodulator and 5-ASA maintenance but not steroids |
| 5 | Rana F, Shaikh M, Bowles J. [10] | UK (2014) | 75M | Infliximab (x2 doses) | UC | Required recurrent courses of steroids for multiple flares, mercaptopurine | *L. monocytogenes* meningitis; hydrocephalus and elevated intracranial pressure | Required to be intubated and ventilated; ventricular drain inserted by neurosurgery service; patient gradually recovered and discharged home after protracted hospital stay |
| 6 | Issa I, Eid A. [11] | Beirut, Lebanon (2013) | 59M | Infliximab (x1 dose) | UC | Prednisolone 30 mg/day, azathioprine | *L. monocytogenes* meningitis | Empiric treatment with ceftriaxone & vancomycin; later switched to ampicillin; deteriorated clinically and suffered cardiopulmonary arrest; passed away 14 days later due to multi-organ failure |
| 7 | 39M | Infliximab (x1 dose) | UC | Prednisolone 40 mg/day, azathioprine | *L. monocytogenes* meningitis | Treated with 21-day course of ampicillin; completely recovered and infliximab never needed to be restarted |
| 8 | Gray J, Allen P, Diong K, Kane M, Varghese A. [12] | Northern Ireland  (2013) | 65M | Infliximab (x1 dose) | Crohn’s colitis | Corticosteroids, azathioprine | *L. monocytogenes* bacteremia | As per paper, both patients had good response to intravenous amoxicillin |
| 9 | 50M | Infliximab | UC |
| 10 | Katsanos K, Kostapanos M, Zois C, Vagias I, Limberopoulos E, Christodoulou D et al. [13] | Greece (2010) | 76M | Infliximab (x1 dose) | Left-sided UC | Corticosteroids (including methylprednisolone 24 mg)  Azathioprine | *L. monocytogenes* bacteremia | Treated with garamycin & ampicillin; started on empiric tazobactam/piperacillin (Tazocin); methylprednisolone dose decreased to 18 mg; was well on discharge and team considered to restart patient on anti-TNF agent |
| 11 | Williams G, Khan A, Schweiger F. [14] | New Brunswick (2005) | 37M | Infliximab (x2 infusions) | Severe Crohn’s colitis | Prednisolone 35 mg/day (as well as IV methylprednisolone)  Azathioprine | *L. monocytogenes* meningitis | Complete patient recovery with no adverse neurological sequelae; achieved remission with 4 grams of 5-ASA and 2.5 mg/kg/day of azathioprine |
| 12 | Lamdhade SJ, Thussu A, Al Benwan KO and Alroughani R [15] | Kuwait (2013) | 28F | Infliximab (x3 doses) |  | Prior immunosuppression and recent infliximab for UC; pregnancy confirmed at 2nd infliximab infusion | *L. monocytogenes* meningitis | Managed with ampicillin and gentamicin; unfortunate spontaneous intrauterine death of fetus at 15 weeks’ gestation |
| 13 | Rani U, Rana A. [16] | Syracuse, NY (2021) | 8F | Infliximab (x2 infusions) | CD | IV steroids | *L. monocytogenes* meningitis | Started on ceftriaxone and vancomycin for empiric cover however changed to ampicillin and gentamicin once Listeriosis confirmed; tapering prednisolone regimen for CD; commenced on MTX 1 month after completing antibiotic regimen as parents wanted to avoid biological agents; however, relapse of GI symptoms occurred despite MTX treatment for 2 months; subsequently, she was started on Vedolizumab; at 6-month clinic follow-up tolerating Vedolizumab and MTX combination therapy well |
| 14 | Slifman N, Gershon S, Lee J, Edwards E, Braun M. [17] – table adopted and adapted from this paper | US | 67M | Infliximab (x3 doses) | CD | Prednisolone 40 mg once daily  Azathioprine | *L. monocytogenes* bacteremia | Recovery as per paper |
| 15 | US | 17F | Infliximab (x1 dose) | CD | Methylprednisolone  Mercaptopurine | *L. monocytogenes* bacteremia; probable meningitis (CSF leucocytosis) | Recovery as per paper |
| 16 | US | 80M | Infliximab (x2 doses) | RA | Prednisolone 15 mg once daily | *L. monocytogenes* bacteremia; meningitis | Death |
| 17 | US | 74F | Infliximab (x6 doses) | RA | Prednisolone 15 mg once daily  MTX 17.5 mg once weekly | *L. monocytogenes* meningitis | Death |
| 18 | US | 78M | Infliximab (x3 doses) | RA | MTX 20 mg once weekly | *L. monocytogenes* meningitis | In coma at time of report |
| 19 | US | 73F | Infliximab (x2 doses) | RA | Prednisolone  MTX  MMF | *L. monocytogenes* bacteremia; possible meningitis | Death; acute myocardial infarction and ventilator-related pneumonia followed closely by multi-organ failure |
| 20 | US | 74F | Infliximab (x5 doses) | RA | Prednisolone 3 mg once daily  MTX 7.5 mg once weekly  Hydroxychloroquine | *L. monocytogenes* bacteremia | Recovery |
| 21 | US | 73M | Infliximab | Not reported | Prednisolone  MTX 50 mg IM  Leflunomide | *L. monocytogenes* meningitis | Not reported |
| 22 | Canada | 64F | Infliximab (x1 dose) | CD | Prednisolone 7.5-40 mg once daily  Mercaptopurine | *L. monocytogenes* bacteremia | Recovery however died 4 months later due to unknown cause |
| 23 | Sweden | 39F | Infliximab (x3 doses) | CD | Prednisolone 45 mg once daily  Mercaptopurine | *L. monocytogenes* bacteremia; *meningitis* | Recovered however residual unilateral ocular palsy |
| 24 | Italy | 20M | Infliximab (x1 dose) | CD | Methylprednisolone 100 mg once daily IV for 6 weeks  Azathioprine | *L. monocytogenes* meningitis | Death |
| 25 | Germany | 60F | Infliximab (x5 doses) | RA | Prednisolone 20 mg once daily  MTX 15 mg  Cyclosporine | *L. monocytogenes* bacteremia; gallbladder infection | Death; cerebral edema |
| 26 | Canada | 60M | Infliximab (x2 doses) | RA | MTX 20 mg once weekly | *L. monocytogenes* bacteremia | Recovery |
| 27 | France | F (age not reported) | Infliximab | RA | Information not provided | *L. monocytogenes* septic arthritis | Not recovered at time of report; continued Infliximab regimen |
| 28 | Norway | 72M | Etanercept | RA | Prednisolone  MTX 10 mg | *L. monocytogenes* bacteremia | Death; acute coronary syndrome & sepsis |
| 29 | Power D, Jackson L, Murphy O, McCarthy J, Horgan M. [18] | Cork, Ireland | 55F | Infliximab (x1 infusion) | UC | Corticosteroids | Pneumocytis pneumonia  *Listeria monocytogenes* meningitis | Received extended course IV amoxicillin for Listeriosis; bronchoalveolar lavage confirmed Pneumocystis pneumonia; initiated dapsone 100mg OD and corticosteroids for concomitant infections; patient had a good clinical outcome |
| 30 | Koklu H, Kahramanoglu Aksoy E, Ozturk O, Gocmen R, Koklu S. [19] | Turkey | 60F | Not initiated on infliximab | UC | Prednisolone 25 mg once daily  Azathioprine 100 mg once daily | *L. monocytogenes* in CSF culture  Left thalamo-mesencephalic abscess | Prednisolone dose gradually reduced;  meropenem & ampicillin administered for CNS infection; meropenem switched to gentamicin, and gentamicin & ampicillin was continued for 1 month; patient clinically improved; control cranial MRI in 6th week showed marked improvement; discharged from hospital on 4 g/day mesalamine |
| 31 | Lee J, Song H, Boo S, Na S, Kim H. [20] | Korea | 75F | Infliximab (x1 dose) | Left-sided UC | Prednisolone | *L. monocytogenes* sepsis | Full recovery after 21-day treatment of IV ampicillin and gentamicin |
| 32 | Reilly E, Hwang J. [21] | USA | 61F | Lenalidomide (one of the mechanisms of action is TNF inhibition) | Multiple myeloma | Not on any immunosuppressants | Listeria cerebritis with bacteremia | Patient passed away on day 17 of admission |
| 33 | Tsuchiya A, Terai S. [22] | Japan | 62F | Infliximab 5 mg/kg every 8 weeks | UC | Mercaptopurine | Listeria colitis progressing to septicemia and meningitis | Ampicillin 12 g/day started; symptoms improved with prolonged 79 day course of antibiotics |
| 34 | Stratton L, Caddy G. [23] | UK | 69M | Infliximab (x1 dose)  *3 days after commencing infliximab* | CD | 5-ASA & Azathioprine failed to achieve remission; steroid-dependent (continuous prednisolone for 7 months prior to admission) | Listeria rhombencephalitis | Deemed unsuitable for surgery; no signs of neurological recovery; repeated episodes of aspiration pneumonia; death 10 months following first infliximab dose |
| 35 | Atsawarungruangkit A, Dominguez F, Borda G, Mavrogiorgos N. [24] | USA | 45F | Adalimumab *Presented 17 days after initiation* | CD | PO prednisolone daily and PO mercaptopurine | *L. monocytogenes* brain abscess | Discharged on day 7 with ampicillin 2 g IV every 4 h for total of 2 weeks; received additional week of trimethoprim/sulfamethoxazole after 3 weeks of ampicillin; repeat MRI performed 4 weeks after initial treatment showed no evidence of ring enhancing lesion |
| 36 | Bowie V, Snella K, Gopalachar A, Bharadwaj P. [25] | USA | 73M | Infliximab (x2 doses) | RA | Concomitant immunosuppression; chronic steroid use | Listeria meningitis | Received 21 days of antibiotic and recovered without any complications |
| 37 | Kesteman T, Yombi J, Gigi J, Durez P. [26] | Belgium | 2 cases | Infliximab (x3 doses) | RA | Glucocorticoids Methotrexate Infliximab | *L. monocytogenes* sepsis; terminal ileitis; bacteremia | Recovered with intravenous sulfamethoxazole-trimethoprim and gentamicin (total duration 30 days antimicrobials). |
| 38 | Glucocorticoids Methotrexate Infliximab | *L. monocytogenes* sepsis; bacteremia associated with prosthetic joint arthritis of left hip | Managed with conservative treatment as patient was not a candidate for removal of prosthesis.  Surgical arthrocentesis performed with long term antibiotic course of amoxicillin. Progressively recovered on follow up. |
| 39 | Horigome R, Sato H, Honma T, Terai S. [27] | Japan | 2 cases | Adalimumab; Golimumab | UC | 5-ASA Prednisolone Infliximab (later switched to Adalimumab) | Septicemic listeriosis | Ampicillin commenced. Continued IBD management with immunomodulators and adalimumab with no progression of pan colitis. |
| 40 | Mesalazine Prednisolone Mercaptopurine Golimumab | Ampicillin commenced. Continued IBD management with golimumab with no further recurrence of UC. |
| 41 | Chuang M, Singh J, Ashouri N, Katz M, Arrieta A. [28] | USA | 17M | Infliximab (x1 dose) | UC | Prednisolone 40 mg BD for 2 weeks followed by 30 mg BD for 6 weeks  Mercaptopurine 75 mg daily for 3 weeks | Listeria meningitis | Required pediatric ICU admission where he required volume support for shock; discharged home on day 15 of admission with plan to complete 21-day course of meropenem, gentamicin and rifampin (amoxicillin allergy) |
| 42 | Boland B, Dulai P, Chang M, Sandborn W, Levesque B. [29] | USA | 19F | Vedolizumab  *Presented to ED 10 days after first infusion* | CD | Ongoing symptoms despite Certolizumab pegol, Azathioprine and budesonide; certolizumab discontinued and Vedolizumab administered; Azathioprine and budesonide continued | Pseudomonas meningitis | Treated with cefepime and recovered; eventually vedolizumab was resumed without azathioprine along with tapering course of prednisolone |
| 43 | Kubota T, Mori Y, Yamada G, Cammack I, Shinohara T, Matsuzaka S et al. [30] | Japan | 73M | Adalimumab 40 mg every 2 weeks for 7 months | RA | Methylprednisolone 8 mg/day  Iguratimod 50 mg/day  Diet comprised on a daily basis of pasteurized milk and cheese; only common raw foods - vegetables and fish consumed in Japan | *L. monocytogenes* ankle osteomyelitis | IV ampicillin and gentamicin initiated; affected bone resected on day 24 and cement fixation was performed; required 2nd operation on day 143 to remove cement and transplant autogenous iliac bone graft as substitute; slow but complete recovery, and gait returned to normal pattern [gentamicin duration 16 days, ampicillin duration 66 days] |
| 44 | Kelesidis T, Salhotra A, Fleisher J, Uslan D. [31] | USA | 42F | Infliximab (received 5 monthly infusions of infliximab 5 mg/kg) | PA | Prior to initiation of infliximab – treated with MTX, etanercept and adalimumab (incomplete clearance of skin lesions and persistent arthralgias) | Listeria endocarditis | Recovered with IV high-dose ampicillin, discharged on 6-week course of antibiotics |

UC: ulcerative colitis; CD: Crohn’s disease; RA: rheumatoid arthritis; PA: psoriatic arthritis; A1: admission 1; A2: admission 2; MTX: methotrexate; MMF: mycophenolate mofetil.

**References**

[2] Abreu, C., Magro, F., Vilas-Boas, F., Lopes, S., Macedo, G. and Sarmento, A., 2013. Listeria infection in patients on anti-TNF treatment: Report of two cases and review of the literature. *Journal of Crohn's and Colitis*, [online] 7(2), pp.175-182. Available at: <https://academic.oup.com/ecco-jcc/article/7/2/175/483879?login=false>.

[8] Parihar V, Maguire S, Shahin A, Ahmed Z, O’Sullivan M, Kennedy M et al. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone. Irish Journal of Medical Science (1971 -) [Internet]. 2015;185(4):965-967. Available from: https://doi.org/10.1007/s11845-015-1355-9

[9] Inoue T, Itani T, Inomata N, Hara K, Takimoto I, Iseki S et al. Listeria Monocytogenes Septicemia and Meningitis Caused by Listeria Enteritis Complicating Ulcerative Colitis. Internal Medicine. 2017;56(19):2655-2659.

[10] Rana F, Shaikh M, Bowles J. Listeria meningitis and resultant symptomatic hydrocephalus complicating infliximab treatment for ulcerative colitis. JRSM Open. 2014;5(3):205427041452222.

[11] Issa I, Eid A. Listeria Meningitis After Infliximab in Ulcerative Colitis: Does the Risk of Treatment Outweigh the Benefit. British Journal of Medicine and Medical Research. 2013;3(4):2008-2016.

[12] Gray J, Allen P, Diong K, Kane M, Varghese A. A CASE SERIES OF LISTERIA MONOCYTOGENES INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH ANTI-TNFα THERAPY. Gut. 2013;62(Suppl 2):A20.2-A20.

[13] Katsanos K, Kostapanos M, Zois C, Vagias I, Limberopoulos E, Christodoulou D et al. Letter to the Editor - Listeria monocytogenes infection two days after infliximab initiation in a patient with ulcerative colitis. ANNALS OF GASTROENTEROLOGY. 2010;23(3):209-210.

[14] Williams G, Khan A, Schweiger F. Listeria Meningitis Complicating Infliximab Treatment for Crohn’s Disease. Canadian Journal of Infectious Diseases and Medical Microbiology. 2005;16(5):289-292.

[15] Lamdhade SJ, Thussu A, Al Benwan KO, Alroughani R. Successful Treatment of Listeria Meningitis in a Pregnant Woman with Ulcerative Colitis Receiving Infliximab. General Medicine: Open Access. 2013;01(03).

[16] Rani U, Rana A. Listeria monocytogenes Meningitis After Treatment With Infliximab in an 8-Year-Old Pediatric Patient With Crohn's Disease. ACG Case Reports Journal. 2021;8(7):e00624.

[17] Slifman N, Gershon S, Lee J, Edwards E, Braun M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor ?-neutralizing agents. Arthritis & Rheumatism. 2003;48(2):319-324.

[18] Power D, Jackson L, Murphy O, McCarthy J, Horgan M. Double Trouble: Pneumocystis Pneumonia and Listeria Meningitis in a patient treated with Infliximab for Ulcerative Colitis - ISG | The Irish Society of Gastoenterology [Internet]. ISG | The Irish Society of Gastoenterology. 2016. Available from: https://isge.ie/abstracts/double-trouble-pneumocystis-pneumonia-listeria-meningitis-patient-treated-infliximab-ulcerative-colitis/

[19] Koklu H, Kahramanoglu Aksoy E, Ozturk O, Gocmen R, Koklu S. An unusual neurological complication in a patient with ulcerative colitis. The Turkish Journal of Gastroenterology. 2017;28(2):137-139.

[20] Lee J, Song H, Boo S, Na S, Kim H. Gut and Liver: Korea Digestive Disease Week 2019 Volume 13·Number 6 (Suppl. 1). Listeria Monocytogenes Sepsis and Meningitis after Infliximab Treatment for Steroid Refractory Ulcerative Colitis. 2019. p. 173.

[21] Reilly E, Hwang J. Listeria Cerebritis with Tumor Necrosis Factor Inhibition. Case Reports in Infectious Diseases. 2020;2020:1-5.

[22] Tsuchiya A, Terai S. Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis. Internal Medicine. 2018;57(17):2603-2603.

[23] Stratton L, Caddy G. Listeria Rhombencephalitis Complicating Anti-TNF Treatment during an Acute Flare of Crohn’s Colitis. Case Reports in Gastrointestinal Medicine. 2016;2016:1-3.

[24] Atsawarungruangkit A, Dominguez F, Borda G, Mavrogiorgos N. Listeria Monocytogenes Brain Abscess in Crohn’s Disease Treated with Adalimumab. Case Reports in Gastroenterology. 2017;11(3):675-679.

[25] Bowie V, Snella K, Gopalachar A, Bharadwaj P. Listeria Meningitis Associated with Infliximab. Annals of Pharmacotherapy. 2004;38(1):58-61.

[26] Kesteman T, Yombi J, Gigi J, Durez P. Listeria infections associated with infliximab: case reports. Clinical Rheumatology. 2007;26(12):2173-2175.

[27] Horigome R, Sato H, Honma T, Terai S. Septicemic listeriosis during adalimumab- and golimumab-based treatment for ulcerative colitis: case presentation and literature review. Clinical Journal of Gastroenterology. 2019;13(1):22-25.

[28] Chuang M, Singh J, Ashouri N, Katz M, Arrieta A. Listeria Meningitis After Infliximab Treatment of Ulcerative Colitis. Journal of Pediatric Gastroenterology &amp; Nutrition. 2010;50(3):337-339.

[29] Boland B, Dulai P, Chang M, Sandborn W, Levesque B. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease. American Journal of Gastroenterology. 2015;110(11):1631-1632.

[30] Kubota T, Mori Y, Yamada G, Cammack I, Shinohara T, Matsuzaka S et al. Listeria monocytogenes Ankle Osteomyelitis in a Patient with Rheumatoid Arthritis on Adalimumab: A Report and Literature Review of Listeria monocytogenes Osteomyelitis. Internal Medicine. 2021;60(19):3171-3176.

**[31]** Kelesidis T, Salhotra A, Fleisher J, Uslan D. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: Are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?. Journal of Infection. 2010;60(5):386-396.